Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 7 of 7 publications.
Skip to main content
Motzer R, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Bennett L, Wang J, Pan JJ, Saretsky TL, Perini RF, He CS, Mody K, Cella D. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Lancet Oncol. 2022 Jun;23(6):768-80. doi: 10.1016/S1470-2045(22)00212-1
Zhou X, Davenport E, Ouyang J, Hoke ME, Garbinsky D, Agarwal I, Krasa HB, Oberdhan D. Pooled data analysis of the long-term treatment effects of tolvaptan in ADPKD. Kidney Int Rep. 2022 Feb 19;7(5):1037-48. doi: 10.1016/j.ekir.2022.02.009
Kuhnen P, Wabitsch M, von Schnurbein J, Chirila C, Mallya UG, Callahan P, Gnanasakthy A, Poitou C, Krabusch PM, Stewart M, Clement K. Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency. Orphanet J Rare Dis. 2022 Feb 5;17(1):38. doi: 10.1186/s13023-022-02186-z
Quam JP, Ackerman SJ, Mordin MM, Bassett LW. Conspicuity and characterization of findings on computed radiography for mammography vs. screen-film mammography: results from a prospective clinical trial. Poster presented at the 89th Scientific Assembly and Annual Meeting of the Radiology Society of North America; November 2003.
Trump DL, Wilding G, Miller K, Small E, Soulie P, Trachtenberg J, Raabe N, Heyes AE, Das-Gupta A. Pilot trials of ZD1839 ('Iressa'), an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor, in combination with mitoxantrone/prednisolone or docetaxel/estramustine in patients with hormone-refractory prostate cancer. Presented at the American Urology Association; April 2003. Chicago, IL.
Ellis CN, Mordin MM, Adler EY. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol. 2003 Feb 1;4(2):131-9.
McLeod LD, Fehnel SE, Brandman J, Symonds T. Evaluating minimal clinically important differences for the acne-specific quality of life questionnaire. Pharmacoeconomics. 2003 Jan 1;21(15):1069-79.